solutions (e.g. HES 10) and also molecules with high MW and greater degree of substitution. 5 8 9 Concerns have also been raised regarding the effects of HES on the coagulation profile. It now seems likely that these solutions will be withdrawn from practice in the care of critically ill patients. 10 11 However, the generalizability of these findings to other patient groups is uncertain and the use of HES for i.v. volume replacement continues in cardiac and non-cardiac surgical patients. There is a paucity of quality data regarding the safety of starch solutions in the surgical population. To compound matters, several studies investigating the use of HES in surgical patients which were conducted by Joachim Boldt have been retracted after allegations of scientific misconduct. 12 At least five meta-analyses on the safety of starch have been published in the last 3 yr. 13 -17 The majority of these reviews have focused on the use of starch in critically ill, septic, or acutely unwell adults. 13 -15 Three of these studies have considered the safety of starch in other groups. The extensive systematic review and meta-analysis conducted by Dart and colleagues included a non-sepsis subgroup largely (but not exclusively) composed of surgical trials. 13 Two further reviews and meta-analyses focus on the use of starch primarily in surgical patients, 15 16 but these are limited because they evaluate only the effects of tetrastach, in some cases in comparison with other starch solutions, and include a heterogeneous group of studies, including those undertaken in trauma, burns, paediatric, and transplant surgery. We undertook a systematic review and meta-analysis on the effect of all 6% HES solutions compared with non-starch solutions in clinical use on mortality and AKI exclusively in the adult surgical population.
Methods

Search strategy
Ovid Medline (1946 -present) 
Study selection criteria
Search results were reviewed and evaluated independently by two authors (R.M.P. and M.S.). Randomized controlled trials (RCTs) in surgical patients were included where hospital mortality, requirement for postoperative renal replacement therapy (RRT), or author-defined postoperative AKI were reported. Trials comparing perioperative administration of 6% HES of any MW or substitution ratio with any non-starch fluid were included, with the exception of trials where comparator fluids were experimental haemoglobin-based fluids (MPOX4 and HBOC21) and hypertonic saline. Trials in subjects undergoing all types of surgery were considered with the exception of neurosurgery, transplantation, burns, or obstetric surgery. Studies where Joachim Boldt was a named author were also excluded. Studies were screened for methodological quality using the Jadad score, an established method of assessing methodological quality of studies to be included in meta-analysis. 19 Assessment was made of the appropriateness of randomization, blinding, and whether patient withdrawal information was provided. The maximum score attributable was 5. Only studies with a Jadad score of ≥3 were included. Disagreements on studies to be included in the final analysis were resolved by consensus within the whole group.
Data extraction
Data extracted for each eligible study included: author; year of publication; surgical group studied; number of subjects; starch used; comparator fluid used; primary and other study outcomes; commercial support; hospital mortality; incidence of postoperative RRT; and incidence of author-defined AKI (where reported).
Outcomes
Primary outcomes studied were hospital mortality and postoperative requirement for RRT. Secondary outcome was the incidence of author-defined postoperative AKI. If data on mortality were not reported, data on AKI or RRT were used; conversely, if data on mortality only were available, then this was used. It was decided a priori that a subgroup analysis would be performed on patients undergoing cardiac surgery.
Statistical analysis
Statistical analysis was carried out using Review Manager (RevMan, v5.2). RevMan is the software used for preparing and maintaining Cochrane Reviews and forms part of the Cochrane Information Management System. Between-study statistical heterogeneity was assessed by x 2 and I 2 tests;
values of the index of 25, 50, and 75% indicated the presence of low, moderate, and high between-trial heterogeneity, respectively. A P-value of 0.1 was considered to denote the statistical significance of heterogeneity. Estimation of potential publication bias used the funnel plot method for any of the outcomes, either primary or secondary. Dichotomous outcomes were expressed as a difference of proportions [risk difference (RD)]. For all analyses performed, if no significant heterogeneity was noted, fixed effect model (FEM) analysis using the Mantel-Haenszel method was used; otherwise, results of the random-effects model analysis using the DerSimonian -Laird method were presented.
Results
Study selection
The process for literature search and study selection is outlined in Figure 1 . Four hundred and fifty-six non-duplicate citations were screened; of which, 34 studies underwent full scoring and data extraction. However, only 19 trials were suitable for inclusion in the meta-analysis, including a total of 1567 subjects. 9 20 -37 Characteristics of included studies
The characteristics of included studies are summarized in Table 1 . Two trials were multicentre trials, the remainder were single-centre trials. In 10 studies, the subjects were undergoing cardiac surgery; two studies were of patients undergoing major vascular surgery and one was a mixture of cardiac and major vascular surgery. The study undertaken by Gondos and colleagues was in a mixed group of surgical patients including those undergoing cardiac surgery. Two trials used HES 450/0.7 and one HES 400/0.7; the remainder used molecular sizes of ≤200 kDa. Comparators included crystalloid solutions, gelatin solutions, and albumin. In seven studies, there was a commercial sponsor. Funnel plot of studies used in the hospital mortality analysis showed no evidence of publication bias (Supplementary material). Studies excluded after full scoring and data extraction were conducted are summarized in Table 2 . In six of these studies, hospital mortality, incidence of RRT, or AKI was not reported. 38 -43 The remainder were excluded, because the Records identified through database searching:
Records identified through additional sources:(n=11)
Records after duplicates removed (n=456)
Inclusion/exclusion criteria applied
Articles excluded after title/abstract screen:
Full-text articles screened:
Full-text articles scored:
Articles included in data synthesis: (n=19) Incidence of postoperative death and acute kidney injury (Fig. 2) .
Secondary outcomes
Incidence of author-defined AKI (Fig. 3) . (Fig. 4) .
Studies involving tetrastach only
Nine studies (n¼856) compared tetrastach (substitution ratio of 0. 4 
Discussion
The principal finding of this systematic review and meta-analysis was that there was no difference in hospital mortality associated with the use of 6% HES solution in the treatment of patients undergoing surgery. Similarly, there were no differences in the secondary outcomes of AKI and the use of RRT. These findings were consistent in subgroup analyses of patients undergoing cardiac and non-cardiac surgery and in patients receiving tetrastarch only. In total, 19 studies with ,1600 participants were suitable for inclusion in the meta-analysis. Seven of the included studies were commercially sponsored, raising the possibility of publication bias (although we found no evidence of this). Despite widespread use for more than three decades, studies comparing perioperative use of HES with other i.v. fluids are small, largely single centre and vulnerable to bias. The most likely cause of HES-associated harm (and hence increased mortality) in the critically ill is causation or exacerbation of kidney injury. However, 52 and in those that did, patients may not have been systematically followed up for these outcomes. All studies reporting postoperative RRTdescribe either no difference or increased use of RRT in the HES group; however, this tendency towards increased use of RRT in the HES group was not statistically significant. The incidence of death, use of RRT and AKI is higher in the critically ill than in the surgical population and it is therefore possible that the low event rates for both death and AKI in included studies resulted in insufficient statistical power to detect a difference in these outcomes. It remains possible that HES solutions are associated with either undetected harm or benefit in the surgical population. We believe that our approach offers significant advantages over previously published work investigating the effects of starch solutions in surgical patients. The non-sepsis subgroup of the meta-analysis undertaken by Dart and colleagues included studies by Boldt, and those enrolling trauma paediatric and renal transplant patients. They also include four studies of 10% HES which is no longer in common use. 13 The study by Van der Linden and colleagues 17 also included studies of paediatric patients, trauma and burns. These heterogeneous groups were excluded from our analysis. The reviews conducted by Van der Linden and colleagues and Martin and colleagues only investigated tetrastach and compared it with other solutions, including alternative HES solutions. Moreover, Martin's study, which appears to be industry initiated, investigated only a single product (6% HES 130/0.4, Voluven, Fresenius, Germany). The authors of this study made no assessment of methodological quality of included studies, were supported by Fresenius-Kabi, manufacturers of the HES solution, Voluven, and utilized their 'study tracking system' for the literature search. 16 Several Incidence of postoperative death and acute kidney injury studies included in other meta-analyses were excluded in this analysis. This included the studies by Harten and colleagues 40 (excluded because outcomes and care in the control arm were unclear), Challand and colleagues (excluded because 6% HES may have been used in the control group), 50 and Tiryakioglu and colleagues (excluded because Jadad score was 2 and the incidence of outcomes of interest was not reported). 43 Strengths of our review include a rigorous assessment of methodological quality of identified trials and selection of a homogeneous group of trials of direct relevance to perioperative medicine. The I 2 statistic confirms a low risk of between-study heterogeneity, and this combined with narrow confidence intervals suggests that our findings are valid. There are also potential limitations of this analysis. We included trials of 6% HES solutions of any MW or substitution, and did not restrict inclusion to one particular HES product. It has been suggested that HES solutions with higher MW and greater substitution may be associated with an increased incidence of AKI and use of these solutions has declined in recent years. Included trials were mostly small single-centre trials with a greater possibility of bias. Synthetic colloidal solutions were introduced in the 1960s, 53 without large phase III trials. Despite little published evidence suggesting advantages over other i.v. fluids, and emerging evidence of harm in septic and critically ill patients, they remain a popular choice for perioperative fluid therapy. 40 50 Although our systematic review did not demonstrate any harm associated with the use of 6% HES solutions, these findings cannot be considered definitive. The Crystalloid versus Hydroxyethyl Starch Trial (CHEST) and Scandanavian Starch for Severe Sepsis/Septic Shock (6S) trials have provided robust evidence to the critical care community that resuscitation of the critically ill with 6% HES was associated with an increased incidence of AKI. 6 7 Many surgical patients receiving HES are considered at high risk of both AKI and death and may require periods of critical care after their surgery. The findings of this analysis suggest that although there should be equipoise to conduct such a trial in surgical patients, the low event rates of both death and new requirement for RRT in the surgical population indicate that a very large clinical trial would be required to confirm the safety of starch solutions in surgical patient population.
Conclusion
The principal finding of this study was that there was no difference in hospital mortality, requirement for RRT, or authordefined AKI associated with perioperative use of i.v. 6% HES solutions. Although most studies were small with low event rates, there was little between-study heterogeneity and narrow confidence intervals. A very large randomized trial of 6% HES solutions would be required to demonstrate either significant benefit or harm associated with the use of these solutions in surgical patients. Given the absence of demonstrable benefit, the clear risks in critically ill patients, and the additional cost over more widely used fluids, we are unable to recommend routine clinical use of 6% HES solution in surgical patients.
